Alignment Healthcare (ALHC) Projected to Post Quarterly Earnings on Thursday
Alignment Healthcare (ALHC) is scheduled to release its Q4 2025 earnings after market close on Thursday, February 26th. Analysts are forecasting a loss of $0.15 per share and revenue of $1.0034 billion for the quarter. Despite significant insider selling totaling $42.27 million over the last quarter, the stock has a "Moderate Buy" consensus rating with an average target price of $23.32.
Alignment Healthcare president Maroney sells $618,990 in stock By Investing.com
Dawn Christine Maroney, President of Alignment Healthcare, Inc. (NASDAQ:ALHC), sold 30,000 shares of common stock for $618,990, executed under a pre-arranged trading plan. Despite the insider sale, analysts maintain a positive outlook for ALHC, citing strong membership growth projections and increased price targets from KeyBanc, Piper Sandler, and JPMorgan. The company is expected to report earnings soon and analysts anticipate profitability this year.
Baird's Model Update Suggests Alignment Healthcare, Inc. (ALHC)'s Shares Could Reach $59
Baird has updated its model for Alignment Healthcare, Inc. (ALHC), increasing its price target to $59 from $28 and reiterating an Outperform rating. This suggests a potential 163% upside from its current price. Despite a recent insider sale by CEO John E. Kao, analysts predict profitability for ALHC this year with an expected FY2025 EPS of $0.23.
Baird’s Model Update Suggests Alignment Healthcare, Inc. (ALHC)’s Shares Could Reach $59
Baird has updated its financial model for Alignment Healthcare, Inc. (ALHC), increasing its price target to $28 from $22 and maintaining an Outperform rating. The firm now projects that ALHC shares could reach $59, representing a 163% upside from current prices. Despite a recent sale of shares by CEO John E. Kao, analysts predict profitability for ALHC in 2025, with an expected EPS of $0.23.
Responsive Playbooks and the ALHC Inflection
This article provides an in-depth analysis of Alignment Healthcare Inc. (NASDAQ: ALHC), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It details three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry points, targets, and stop losses. The analysis also includes multi-timeframe signal strengths and key support/resistance levels.
Alignment Healthcare, Inc. (ALHC) Stock Analysis: Revenue Growth Soars as Analysts Eye 24.65% Upside
Alignment Healthcare, Inc. (ALHC) is attracting investor attention due to its impressive 43.50% revenue growth, despite currently being unprofitable with a negative EPS. The company, which specializes in Medicare Advantage plans for seniors, has a market cap of $4.04 billion and a free cash flow of $178.6 million. Analysts have issued 10 buy ratings and 2 hold ratings, projecting an average potential upside of 24.65% from its current price.
Do Insider Sales at Alignment Healthcare (ALHC) Complicate the Story of Its Rapid Membership Expansion?
Alignment Healthcare (ALHC) recently reported strong health plan membership growth and projected further expansion, while its CEO and CHRO conducted routine share sales. The article examines whether these insider sales complicate the narrative of the company's rapid growth, emphasizing that strong membership momentum and analyst upgrades are shaping investor expectations. However, it also highlights the importance of the company's technology initiatives and the potential impact of regulatory changes on its profitability.
Do Insider Sales at Alignment Healthcare (ALHC) Complicate the Story of Its Rapid Membership Expansion?
Alignment Healthcare (ALHC) recently announced strong health plan membership growth projections for 2026, following significant year-over-year increases. Despite routine insider sales by the CEO and CHRO, the company's operating performance and the success of its technology-driven care platform (AVA) are key to converting this growth into sustainable profitability. Investors are weighing the membership momentum against potential regulatory changes and analyst caution regarding future earnings.
Caisse Des Depots ET Consignations Lowers Stock Holdings in Alignment Healthcare, Inc. $ALHC
Caisse Des Depots ET Consignations significantly reduced its stake in Alignment Healthcare, Inc. by 48.5% in the third quarter of 2026, selling 77,131 shares and retaining 82,053 shares valued at approximately $1.43 million. This comes amidst broader insider selling, with CEO John E. Kao selling 180,000 shares for $3.69 million and other insiders selling 2.12 million shares worth about $41.7 million in the last quarter. Despite this, analysts maintain a "Moderate Buy" rating for ALHC with an average target price of $23.32.
Alignment Healthcare CHRO Wagner sells $455k in shares
Alignment Healthcare's Chief Human Resources Officer, Andreas P. Wagner, sold 22,238 shares for approximately $455,211 to cover tax withholding obligations. This transaction comes amidst positive developments for the company, including projected membership growth of 24-27% for 2026 and boosted price targets from KeyBanc, Piper Sandler, and an upgrade from JPMorgan for its strong performance and growth potential in the Medicare Advantage sector.
Insider Selling: Alignment Healthcare (NASDAQ:ALHC) Insider Sells 22,238 Shares of Stock
Andreas Wagner, an insider at Alignment Healthcare (NASDAQ:ALHC), sold 22,238 shares of the company's stock on February 10th for approximately $455,212. This transaction reduced his stake by 11.58% to 169,805 shares. The company has a market capitalization of $4.13 billion and analyst sentiment is "Moderate Buy" with an average target price of $23.32, while institutional ownership stands at about 86%.
Alignment Healthcare (NASDAQ:ALHC) CEO Sells $3,688,200.00 in Stock
Alignment Healthcare (NASDAQ:ALHC) CEO John Kao sold 180,000 shares of the company's stock for a total of $3,688,200.00 on February 10th. This transaction reduced his stake by 6.35% to 2,652,641 shares. Despite the insider sale, analysts maintain a "Moderate Buy" consensus rating for ALHC with an average target price of $23.32.
Alignment Healthcare CHRO Wagner sells $455k in shares By Investing.com
Alignment Healthcare's CHRO, Andreas P. Wagner, sold 22,238 shares for $455,211 to cover tax obligations, not as a discretionary trade. The company is experiencing significant growth, with projected health plan membership increases and raised price targets from KeyBanc, Piper Sandler, and JPMorgan, indicating strong performance in the Medicare Advantage sector.
Alignment Healthcare schedules Feb. 26 review of 2025 results
Alignment Healthcare (NASDAQ: ALHC) will announce its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 26, 2026, after market close. This will be followed by a conference call at 5:00 p.m. EST. A live audio webcast will be available, and a replay will remain online for approximately 12 months, according to the company.
Alignment Healthcare, Inc. (NASDAQ:ALHC) Receives Average Rating of "Moderate Buy" from Analysts
Alignment Healthcare, Inc. (NASDAQ:ALHC) has received an average rating of "Moderate Buy" from fourteen analysts, with an average 12-month price target of $23.05. Despite significant insider selling over the last quarter, institutional ownership remains high at 86.19%. The stock has recently traded around $22.65, boasting a $4.53 billion market capitalization.
Alignment Healthcare (NASDAQ:ALHC) Upgraded by Wall Street Zen to Buy Rating
Wall Street Zen has upgraded Alignment Healthcare (NASDAQ:ALHC) from a "hold" to a "buy" rating, contributing to an average "Moderate Buy" rating among analysts with a $23.32 target price. Despite recent insider selling totaling $40.53 million, institutional investors hold a significant majority of the stock. Shares are currently trading around $21.75, showing a positive movement of approximately 2.8%.
Has Alignment Healthcare (ALHC) Run Ahead Of Its Value After Recent Share Price Strength?
Alignment Healthcare (ALHC) shares recently closed at US$21.75, showing a 1-year return of 47.6%. A Discounted Cash Flow analysis suggests the stock is currently 16.9% overvalued, with an estimated intrinsic value of US$18.60 per share, while a Price-to-Sales ratio analysis indicates it is priced broadly in line with its fair value. Investors are encouraged to use "Narratives" on Simply Wall St to align their personal valuation assumptions with the company's financial forecasts.
J.P. Morgan Keeps Their Buy Rating on Alignment Healthcare (ALHC)
J.P. Morgan analyst John Stansel maintained a Buy rating on Alignment Healthcare (ALHC) with a price target of $26.00. This comes as the company reported a significant increase in quarterly revenue to $993.7 million, though corporate insider sentiment appears negative due to recent share sales. Other analysts also weighed in on ALHC, with Robert W. Baird issuing a Buy, while TipRanks – xAI reiterated a Hold rating.
Alignment Healthcare to Announce Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call Thursday, Feb. 26, 2026
Alignment Healthcare (NASDAQ: ALHC) will release its fourth quarter and full-year 2025 financial results on Thursday, Feb. 26, 2026, after market close. The company will host a conference call at 5 p.m. EST to discuss the results, with a live audio webcast available online and a replay accessible for approximately 12 months. Alignment Health focuses on providing high-quality, low-cost Medicare Advantage care, utilizing a customized care model and technology.
6 Analysts Have This To Say About Alignment Healthcare
Six analysts have provided a range of ratings for Alignment Healthcare (NASDAQ: ALHC) over the last quarter, with sentiment leaning towards bullish or somewhat bullish. The average 12-month price target has increased by 23.44% to $24.17 from the prior $19.58, with a high estimate of $30.00 and a low of $20.00. The company's financials show strong revenue growth and impressive ROE and ROA, but challenges in market capitalization, net margin, and debt management.
Alignment Healthcare to Announce Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call Thursday, Feb. 26, 2026
Alignment Healthcare, Inc. (NASDAQ: ALHC) is scheduled to release its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, after the market closes. The company will then host a conference call at 5 p.m. EST to discuss these results. A live audio webcast will be accessible online, and a replay will be available for approximately 12 months after the call.
Alignment Healthcare Inc (NASDAQ:ALHC) Combines High-Growth Momentum with a Bullish Technical Setup
Alignment Healthcare (NASDAQ:ALHC) has been identified through a multi-layered screening method combining High Growth Momentum, Technical Analysis, and Setup Quality ratings. The company exhibits strong revenue growth, improving profitability, and positive analyst revisions, supported by a robust technical chart showing an uptrend and favorable consolidation patterns. This suggests a potentially opportune entry point for investors seeking fundamentally strong companies with momentum.
Alignment Healthcare (ALHC) Price Target Increased by 11.78% to 25.42
The average one-year price target for Alignment Healthcare (NasdaqGS:ALHC) has been increased by 11.78% to $25.42 per share from a prior estimate of $22.74. This target represents a 19.10% increase from the last closing price of $21.34. The article also details institutional ownership changes, highlighting key holders like General Atlantic and T. Rowe Price Investment Management.
A Look At Alignment Healthcare (ALHC) Valuation After Upbeat Analyst Commentary And Target Raises
Alignment Healthcare (ALHC) has garnered increased investor attention following positive analyst commentary and price target raises, leading to a 4% share price bump and significant recent returns. Despite this momentum and strong growth prospects from its technology-enabled care model, the stock is currently trading about 9% below the average analyst target and is considered overvalued by Simply Wall St's narrative valuation at $22.89 against a fair value of $21.04. The company faces potential headwinds from Medicare Advantage reimbursement changes and increased competition, which could impact margins and membership growth.
A Look At Alignment Healthcare (ALHC) Valuation After Upbeat Analyst Commentary And Target Raises
Alignment Healthcare (ALHC) has garnered increased investor attention following positive analyst commentary and target price raises, leading to a 4% surge in its share price. Despite recent strong share price performance and trading close to analyst targets, Simply Wall St assesses ALHC as "9% Overvalued" based on its narrative fair value of $21.04 against a last close of $22.89. The company's technology-enabled care model could lead to margin expansion, though potential changes to Medicare Advantage reimbursement and competition pose risks.
Alignment Healthcare, Inc. (ALHC) Stock Analysis: Exploring a 10% Potential Upside in Healthcare Plans
Alignment Healthcare, Inc. (ALHC) is emerging as a significant player in the healthcare sector, particularly with its focus on Medicare Advantage plans for seniors, boasting a market cap of $4.53 billion and robust 43.50% revenue growth. Despite not yet achieving profitability (negative EPS and ROE), the company has strong free cash flow and a positive analyst outlook with an average target price suggesting a 10% potential upside. Technical indicators also point towards a potential bullish momentum for ALHC.
Federated Hermes Inc. Sells 149,304 Shares of Alignment Healthcare, Inc. $ALHC
Federated Hermes Inc. reduced its stake in Alignment Healthcare by 25.1%, selling 149,304 shares and now holding 445,185 shares valued at approximately $7.77 million. While institutional ownership remains high at 86.19% due to other firms increasing their positions, insiders have sold over 2 million shares in the last 90 days. Analysts maintain a "Moderate Buy" rating with a consensus target price of $23.05 for the company.
Is Alignment Healthcare’s New CDO Hire a Turning Point in Its AI Strategy for Medicare (ALHC)?
Alignment Healthcare recently appointed Adnan Mansour as Chief Digital Officer, signaling a deeper integration of AI into its Medicare Advantage operations, particularly with the AVA platform. This strategic hire comes amidst increasing regulatory scrutiny and payment policy changes in the Medicare Advantage sector. The company hopes that AI can improve operational efficiency and care outcomes to mitigate potential impacts from tighter reimbursement rules, though insider selling and current valuations suggest execution risks remain.
Teacher Retirement System of Texas Buys 47,472 Shares of Alignment Healthcare, Inc. $ALHC
The Teacher Retirement System of Texas significantly increased its stake in Alignment Healthcare (ALHC) by 85.8% in Q3, purchasing an additional 47,472 shares, bringing its total to 102,827 shares valued at approximately $1.79 million. Despite this institutional buying, insiders have recently sold over 2.1 million shares worth more than $40 million. Alignment Healthcare reported a strong Q3 with an EPS beat and revenue of $993.7 million, up 43.5% year-over-year, and analysts generally rate the stock a "Moderate Buy" with an average price target of $23.05.
Stocks making big moves yesterday: Manhattan Associates, Alignment Healthcare, Microchip Technology, Provident Financial Services, and F5
This article highlights several companies whose stocks experienced significant movement yesterday. Manhattan Associates (MANH) fell after a weak earnings forecast despite strong Q4 results, while Alignment Healthcare (ALHC) rose due to a positive analyst outlook. Microchip Technology (MCHP) saw an increase following an upgrade from Bank of America, and Provident Financial Services (PFS) gained after beating earnings expectations. F5 (FFIV) also rose significantly, driven by strong Q4 earnings and an optimistic forecast.
Stocks making big moves yesterday: Manhattan Associates, Alignment Healthcare, Microchip Technology, Provident Financial Services, and F5
This article reports on five companies that experienced significant stock movements yesterday. Manhattan Associates fell due to a weaker-than-expected earnings forecast despite strong Q4 results, while Alignment Healthcare rose after positive analyst comments. Microchip Technology saw an increase following an analyst upgrade, and Provident Financial Services and F5 both climbed after reporting better-than-expected earnings and optimistic forecasts.
Stocks making big moves yesterday: Manhattan Associates, Alignment Healthcare, Microchip Technology, Provident Financial Services, and F5
This article details the stock performance of several companies from yesterday's trading. Manhattan Associates saw a decline after a weaker 2026 earnings forecast despite strong Q4 results, while Alignment Healthcare, Microchip Technology, Provident Financial Services, and F5 all experienced gains due to positive analyst comments, upgrades, or better-than-expected earnings reports.
Alignment Healthcare (ALHC) Stock Trades Up, Here Is Why
Shares of Alignment Healthcare (ALHC) rose 4% following optimistic comments from a Baird analyst regarding earnings growth, helping the stock recover from a previous sharp decline. The prior drop was triggered by a disappointing preliminary Medicare Advantage payment proposal from CMS, which suggested only a 0.09% increase, far below analyst predictions. Despite recent volatility, the stock is up 7.4% year-to-date and trading near its 52-week high, indicating a meaningful market response to the Baird analyst's comments.
Alignment Healthcare (ALHC) Stock Trades Up, Here Is Why
Shares of Alignment Healthcare (NASDAQ:ALHC) rose 4% after a Baird analyst reported a promising outlook for earnings growth, helping the stock rebound from a previous sharp decline. This recovery followed a significant drop due to a Centers for Medicare & Medicaid Services (CMS) preliminary payment proposal for Medicare Advantage that proposed a mere 0.09% increase, much lower than analyst expectations. Despite the bounce, the stock had previously fallen 13.9% on the news and is currently trading near its 52-week high, up 7.4% since the beginning of the year.
Why Alignment Healthcare (ALHC) Stock Is Falling Today
Shares of Alignment Healthcare (ALHC) fell significantly after the Centers for Medicare & Medicaid Services proposed a much lower-than-expected 0.09% increase in Medicare Advantage payment rates for 2027. This proposal, far below the anticipated 4% to 6% growth, has raised investor concerns about future profitability for companies reliant on Medicare Advantage plans, impacting the broader health insurance sector. Despite this drop, the company's stock is still up 2.5% year-to-date, though it trades below its 52-week high.
A Look At Alignment Healthcare (ALHC) Valuation After Analyst Upgrades On Medicare Advantage Growth
Alignment Healthcare (ALHC) is gaining attention due to analyst upgrades on Medicare Advantage growth and a new chief digital officer appointment, with the stock showing strong recent and long-term gains. Despite this momentum, Simply Wall St's "Most Popular Narrative" suggests the stock is 13.2% overvalued at $23.81 against a fair value of $21.04, highlighting potential risks like tighter Medicare Advantage reimbursement or increased competition. The analysis is based on detailed assumptions about membership growth, profitability, and an earnings multiple.
Spotting Winners: Alignment Healthcare (NASDAQ:ALHC) And Health Insurance Providers Stocks In Q3
This article reviews the Q3 performance of several health insurance providers, highlighting Alignment Healthcare (NASDAQ:ALHC) as a strong performer with a significant revenue beat and stock increase. It also covers CVS Health (NYSE:CVS) and Molina Healthcare (NYSE:MOH), noting CVS's strong quarter despite a stock dip and Molina's slower performance. The analysis touches on industry trends like an aging population and regulatory scrutiny.
Alignment Healthcare (ALHC) Drops 12% on Medicare Flat Funding
Alignment Healthcare Inc. (ALHC) shares dropped 12% following a lower-than-expected preliminary payment proposal for the Medicare Advantage program, which projected only a 0.09% increase in net average payment instead of the anticipated 4-6% growth. The Centers for Medicare and Medicaid Services (CMS) also proposed stricter risk-adjustment rules. This news impacted other listed insurers with exposure to the government-sponsored program, and investors are now awaiting ALHC's short-term outlook and upcoming financial results in late February 2026.
A Look At Alignment Healthcare (ALHC) Valuation After Analyst Upgrades On Medicare Advantage Growth
Alignment Healthcare (ALHC) is gaining analyst attention due to Medicare Advantage subscriber growth and a new chief digital officer appointment. Despite strong past share price performance, the stock is currently seen as 13.2% overvalued with a fair value of $21.04, trading at $23.81. The valuation considers the company's technology-enabled care model, potential for margin expansion, and long-term growth opportunities in an aging population, but also highlights risks like reimbursement pressure and increased competition.
Why Alignment Healthcare (ALHC) Stock Is Falling Today
Shares of Alignment Healthcare (ALHC) fell significantly after the Centers for Medicare & Medicaid Services (CMS) proposed a much lower-than-expected 0.09% increase in Medicare Advantage payment rates for 2027, instead of the anticipated 4-6% growth. This news negatively impacted the entire health insurance sector, raising concerns about future profitability for companies reliant on Medicare Advantage plans. Despite the current dip, the company had shown positive performance earlier in the year and strong growth in the fourth quarter of 2024.
10 Big Names With Painful Declines
Alignment Healthcare Inc. (NASDAQ:ALHC) experienced a significant 11.97% decline after the Centers for Medicare and Medicaid Services (CMS) released lower-than-expected preliminary payment proposals for the Medicare Advantage program. The proposed net average payment increase of only 0.09% disappointed analysts who anticipated 4-6% growth, leading to a sell-off in listed insurers. Investors are now closely watching Alignment Healthcare Inc.'s short-term outlook, with its next earnings report expected in late February 2026.
Alignment Healthcare Inc (ALHC) Shares Down 15.01% on Jan 27
Alignment Healthcare Inc (ALHC) shares dropped 15.01% on January 27, reaching an intraday low of $19.97 before closing at $20.24. This places the stock significantly below its 52-week high but well above its 52-week low. Wall Street analysts maintain an "Outperform" rating, with an average target price suggesting an upside of 16.95%, while GuruFocus estimates an 8.22% upside based on its GF Value.
A Look At Alignment Healthcare (ALHC) Valuation After Analyst Upgrades On Medicare Advantage Growth
Alignment Healthcare (ALHC) is gaining momentum following analyst upgrades related to Medicare Advantage subscriber growth and earnings. The company, which recently appointed a new chief digital officer, is seen as overvalued at its current price of $23.81 compared to a narrative-based fair value of $21.04. Despite strong share price performance and long-term gains, the valuation hinges on assumptions about Medicare Advantage margins and future earnings power.
Y Intercept Hong Kong Ltd Acquires New Stake in Alignment Healthcare, Inc. $ALHC
Y Intercept Hong Kong Ltd has acquired a new stake of 200,489 shares in Alignment Healthcare, Inc. (NASDAQ:ALHC), valued at approximately $3.5 million. This acquisition, alongside increased positions by other institutional investors like Invesco and Hood River, brings the total institutional ownership of Alignment Healthcare to about 86.19%. Despite recent insider selling, analysts generally maintain a "Moderate Buy" rating for the company with a consensus price target of $22.50.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
This article identifies 12 healthcare stocks experiencing significant movement in Tuesday's pre-market session, categorized into gainers and losers. Notable gainers include Nuwellis (NASDAQ: NUWE) and Genenta Science (NASDAQ: GNTA), while losers include Alignment Healthcare (NASDAQ: ALHC), Humana (NYSE: HUM), and UnitedHealth Group (NYSE: UNH). The report provides percentage changes and market capitalization for each listed company, noting that UnitedHealth Group's decline followed Q4 earnings.
Alignment Healthcare (NASDAQ:ALHC) Reaches New 1-Year High - Time to Buy?
Alignment Healthcare (NASDAQ:ALHC) recently hit a new 52-week high of $23.87, with market capitalization of $4.76 billion and a "Moderate Buy" consensus rating from analysts, who anticipate an average price target of $22.50. Despite beating EPS estimates and showing strong revenue growth, the company still reports negative net margin and ROE, with expected negative EPS for the current year. Insider selling has significantly occurred over the last 90 days, while institutional investors hold a substantial portion of the shares.
Is Alignment Healthcare’s (ALHC) New CDO Hire the Missing Link in Its AI-Driven Medicare Strategy?
Alignment Healthcare recently appointed Adnan Mansour as Chief Digital Officer to strengthen its AI-powered AVA platform and unify its technology. This strategic move aligns with the company's focus on leveraging AI and data for profitable scaling of its Medicare Advantage model, despite current unprofitability and execution risks. The market is showing varying fair value estimates for ALHC, suggesting diverse perspectives on its future performance.
Is Alignment Healthcare (ALHC) Pricing Justified After 62% One Year Share Price Gain
Alignment Healthcare (ALHC) has seen a 62% share price increase over the past year, closing recently at US$23.61. Simply Wall St's analysis suggests the stock may be overvalued, with a Discounted Cash Flow (DCF) model indicating a 35.6% premium to its intrinsic value of $17.42 per share. While its Price/Sales ratio of 1.30x is near the industry average, Simply Wall St's proprietary Fair Ratio of 1.19x still flags it as slightly expensive.
Analysts Are Bullish on These Healthcare Stocks: Invivyd (IVVD), Alignment Healthcare (ALHC)
This article highlights analysts' bullish sentiments on several healthcare stocks, focusing on Invivyd (IVVD) and Alignment Healthcare (ALHC). H.C. Wainwright maintained a Buy rating for Invivyd with a $10.00 price target, while KeyBanc maintained a Buy rating for Alignment Healthcare with a $28.00 price target. Johnson & Johnson (JNJ) also received a Buy rating from RBC Capital with a $240.00 price target.
Alignment Healthcare stock price target raised to $28 by KeyBanc
KeyBanc has increased its price target for Alignment Healthcare Inc (NASDAQ:ALHC) to $28.00 from $21.00, maintaining an Overweight rating, citing anticipated membership growth of 24-27% by year-end 2026 and EBITDA guidance aligning with current consensus. The firm views the 2026 outlook positively, noting strong performance and potential for further operational improvements. Other firms like Piper Sandler, JPMorgan, and Goldman Sachs have also revised their targets upwards or upgraded the stock based on recent strong results and growth projections.
